21 Lp(a) and PAD Toolkit: Emerging Diagnosis and Management Glossary Apo(a) . . . . . . . Apolipoprotein(a) ApoB . . . . . . . . . . . . . . . . Apolipoprotein B ASCVD . . . . . . . Atherosclerotic Cardiovascular Disease CHD . . . . . . . . Coronary Heart Disease CKD . . . . . . . . Chronic Kidney Disease FH . . . . . . . . . Familial Hypercholesterolemia HCP . . . . . . . . Health Care Professionals HoFH . . . . . . . . Homozygous Familial Hyperlipidemia LDL-C . . . . . . . . Low Density Lipoprotein Cholesterol Lp(a) . . . . . . . . Lipoprotein(a) (pronounced L-P-little-A) 36 MACE . . . . . . . . Major Adverse Cardiovascular Event MALE . . . . . . . . Major Adverse Limb Event PAD......... Peripheral Artery Disease PVD......... Peripheral Vascular Disease PCSK9 inhibitors . . . PCSK9 Monoclonal Antibody siRNA . . . . . . . . Small Interfering RNA TASC . . . . . . . TransAtlantic Inter-Society Consensus For more information on Lp(a), scan the QR code to download Lp(a): A Toolkit for Health Care Professionals. Lp(a):A Toolkit for Health Care Professionals Novartis is proud to support the American Heart Association’s Lp(a) Awareness and Testing Initiative.
RkJQdWJsaXNoZXIy MjI2NjI=